Important Opportunity for REGENXBIO Investors in Securities Fraud Case

REGENXBIO Investors: A Chance to Take Action

Investors who acquired securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022, and January 27, 2026, are reminded of an important opportunity to assert their rights. The Rosen Law Firm, a prominent global law firm specializing in investor rights, has announced a lead plaintiff deadline of April 14, 2026, for those who might be eligible to join a class action lawsuit related to alleged securities fraud.

Why This Matters

If you purchased REGENXBIO securities during the specified period, you may be entitled to compensation without any upfront fees, thanks to a contingency fee arrangement. This means that you don't have to pay out of pocket to get involved – the firm only gets paid if you win your case.

Steps to Get Involved

For those interested in joining the action, the process is straightforward. Potential class members can visit Rosen Legal's Website to submit their information or call Phillip Kim, Esq., toll-free at 866-767-3653. You can also email [email protected] for additional details. It’s crucial to act before the April 14 deadline if you wish to serve as a lead plaintiff, which involves representing other class members and directing the litigation.

The Background of the Lawsuit

According to the allegations posed in the lawsuit, REGENXBIO was accused of misleading investors about its gene therapy product candidate RGX-111, which targets the treatment of Mucopolysaccharidosis Type I, also known as Hurler syndrome. The defendants purportedly communicated overly optimistic assertions regarding the success of RGX-111's trials, underpinned by positive biomarker data from ongoing studies.

However, the lawsuit claims that alongside these optimistic proclamations, the company concealed material facts that could have adversely affected the perceived safety and efficacy of the RGX-111 clinical studies. When these realities emerged, it caused significant losses to investors, as they suffered financial damages stemming from the misinformation spread by the defendants.

Why Choose Rosen Law Firm?

Choosing the right legal counsel can make a significant difference in the outcome of a securities fraud case. The Rosen Law Firm has a strong track record in handling complex securities class actions and has achieved substantial settlements in the past. With accolades, such as being ranked the number one firm for securities class action settlements in 2017, and the distinction of securing over $438 million for investors in 2019 alone, the firm holds an extensive background that is beneficial for potential class members seeking representation.

The firm emphasizes the importance of aligning with experienced counsel rather than firms that may lack the necessary resources or expertise to efficiently handle class action lawsuits.

Investors are encouraged to stay updated by following the Rosen Law Firm on various platforms, including LinkedIn, Twitter, and Facebook, to get the latest news regarding the lawsuit and other investor rights matters.

Important Notices

Currently, no class has been certified. Until a class is certified, interested parties are not represented unless they retain legal counsel of their choosing. It should also be noted that individual investors have the option to remain absent from the class action process or to take no action if they prefer.

Don't miss out on this opportunity to potentially recover losses and hold accountable those who may have misled investors regarding REGENXBIO's efforts and promises. Make sure to consider your position as an investor in these critical days leading up to the April 14 deadline.